LABORATORIOS FARMACEUTICOS ROVI, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85 EUR | +0.35% |
|
+7.05% | +41.20% |
| 04-02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
| 03-12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
Chart calendar Laboratorios Farmaceuticos Rovi, S.A.
cbe15b622f910569.z9ng41hMI4dIi8Mgp4OlqymfDzi-AqINQIiripA9AqY.hYam2z86R-QwppBu3ebo_2fqa0vueMpndrqd-sB2b5W_m6qpIjVbsRn_8w~4a5d65996432bd642d7619551f570287
Upcoming events on Laboratorios Farmaceuticos Rovi, S.A.
Past events on Laboratorios Farmaceuticos Rovi, S.A.
| 27/02/2024 14:00 | Q4 2023 Earnings Call |
| 26/02/2024 | Q4 2023 Earnings Release Pre-market |
| 07/11/2023 | Q3 2023 Earnings Call |
| 07/11/2023 | Q3 2023 Earnings Release Pre-market |
| 26/07/2023 14:00 | Q2 2023 Earnings Call |
| 25/07/2023 | Q2 2023 Earnings Release Pre-market |
| 02/07/2023 | Ex-dividend day for final dividend |
| 14/06/2023 10:00 | Annual General Meeting |
| 09/05/2023 | Q1 2023 Earnings Call |
| 09/05/2023 | Q1 2023 Earnings Release Pre-market |
| 21/02/2023 09:00 | FY 2022 Earnings Call |
| 20/02/2023 | FY 2022 Earnings Release Pre-market |
| 23/11/2022 09:00 | Capital Market Day |
| 03/11/2022 | Q3 2022 Earnings Call |
| 03/11/2022 | Q3 2022 Earnings Release Pre-market |
| 27/07/2022 14:00 | Interim 2022 Earnings Call |
| 26/07/2022 | Interim 2022 Earnings Release Pre-market |
| 04/07/2022 | Ex-dividend day for final dividend |
| 10/05/2022 | Q1 2022 Earnings Call |
| 10/05/2022 | Q1 2022 Earnings Release Pre-market |
Past dividends on Laboratorios Farmaceuticos Rovi, S.A.
| 02/07/2023 | Annual 1.047978 EUR |
| 04/07/2022 | Annual 0.774036 EUR |
| 04/07/2021 | Annual 0.308772 EUR |
| 16/11/2020 | Annual 0.141831 EUR |
| 01/07/2019 | Annual 0.064638 EUR |
| 02/07/2018 | Annual 0.097767 EUR |
| 02/07/2017 | Annual 0.14823 EUR |
| 29/06/2016 | Annual 0.11259 EUR |
| 01/07/2015 | Annual 0.1352 EUR |
| 02/07/2014 | Annual 0.127348 EUR |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 381 369 3.33% | 420 417 0.78% | 649 633 2.52% | 818 788 3.78% | 830 823 0.79% | 824 |
|
EBITDA Million EUR | Released Forecast Spread | 60,9 58,2 4.5% | 94,3 88,5 6.59% | 203 193 5.23% | 279 252 10.47% | 245 239 2.36% | 243 |
|
EBIT Million EUR | Released Forecast Spread | 42,6 40,6 5.11% | 74,7 69,9 6.88% | 181 171 5.95% | 256 230 11.48% | 220 214 2.67% | 217 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | 41,9 40,1 4.44% | 72,6 67,9 6.93% | 183 171 7.03% | 258 226 14.07% | 220 217 1.8% | 213 |
|
Net income Million EUR | Released Forecast Spread | 39,3 36,1 8.71% | 61,1 60,4 1.07% | 153 140 9.42% | 200 183 9.36% | 170 167 2.05% | 171 |
|
EPS EUR | Released Forecast Spread | 0,71 0,62 15.01% | 1,10 1,09 0.72% | 2,76 2,51 10.05% | 3,73 3,35 11.19% | 3,20 3,12 2.58% | 3,31 |
| Announcement Date | 26/02/20 | 24/02/21 | 23/02/22 | 21/02/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2020 S1 | 2021 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 191 191 -0.08% | 290 277 4.73% | 185 174 6.55% | 206 201 2.53% | 175 173 1.32% | 380 377 0.78% | 195 193 0.91% | 242 223 8.67% | 202 195 3.15% | 179 174 3.01% | 381 377 1.02% | 214 208 3.05% | 235 226 3.91% | 154 |
|
EBITDA Million EUR | Released Forecast Spread | 42,4 39,8 6.67% | 74,0 74,7 -0.94% | 63,4 55,5 14.09% | 74,3 68,5 8.47% | 41,5 38,5 7.7% | 116 113 2.57% | 58,1 55,2 5.25% | 105 82,1 27.71% | 66,5 59,1 12.57% | 30,6 24,2 26.62% | 97,1 93,0 4.41% | 74,1 66,8 10.93% | 73,3 71,1 3.14% | 26,5 |
|
EBIT Million EUR | Released Forecast Spread | 32,9 30,3 8.63% | 63,2 65,6 -3.6% | 58,2 49,8 16.8% | 68,7 62,0 10.82% | 35,7 33,2 7.33% | 104 102 2.45% | 52,5 49,6 5.89% | 99,0 74,5 32.91% | 60,7 52,8 14.91% | 24,5 19,0 28.98% | 85,2 81,0 5.19% | 68,2 58,5 16.58% | 66,7 66,0 1.06% | 21,2 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | 58,3 44,1 32.15% | 68,9 61,7 11.71% | 61,2 55,3 10.67% | 19,8 | ||||||||||
|
Net income Million EUR | Released Forecast Spread | 29,6 27,3 8.49% | 51,0 50,1 1.84% | 54,1 36,1 50.18% | 53,0 49,5 7.17% | 27,6 25,5 8.2% | 80,6 78,6 2.57% | 40,9 38,2 7.02% | 78,2 59,8 30.82% | 47,5 42,3 12.29% | 19,1 13,6 40.1% | 66,6 63,0 5.71% | 52,2 45,5 14.77% | 51,5 47,7 8.04% | 11,9 |
|
EPS EUR | Released Forecast Spread | 0,98 0,61 60.66% | |||||||||||||
| Announcement Date | 27/07/20 | 28/07/21 | 23/02/22 | 11/05/22 | 27/07/22 | 27/07/22 | 04/11/22 | 21/02/23 | 10/05/23 | 26/07/23 | 26/07/23 | 08/11/23 | 27/02/24 | - |
More events
Past sector events for Laboratorios Farmaceuticos Rovi, S.A.
Net sales - Quarter - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ROVI Stock
- Calendar Laboratorios Farmaceuticos Rovi, S.A.
